Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund
29.5.2026 14:00:00 EEST | Business Wire | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR).
GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people worldwide.
GHIC has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to leverage venture capital investments to accelerate the development and introduction of technologies and medical products that respond to and prevent health security threats. Through this public‑private partnership, GHIC launched GHSF, a pioneering venture capital fund dedicated to supporting innovations that strengthen public health preparedness and build resilient global health systems capable of detecting, preventing, and responding to future public health emergencies.
“Investing in GHIC’s GHSF was a straightforward decision for us,” said Toshiaki Nagasato, President and Representative Director of Meiji Seika Pharma. “GHIC’s mission to address unmet global health needs closely aligns with Meiji Seika Pharma’s long‑standing commitment to infectious disease innovation. We are pleased to participate in GHSF as a limited partner and to collaborate with GHIC’s highly experienced team. Together, we aim to drive meaningful impact in areas such as infectious diseases, where unmet medical needs remain substantial but sustained pharmaceutical engagement has been limited due to challenging market dynamics.”
“Global health security requires sustained investment, continued innovation, and strong collaboration across the public and private sectors,” said Labeeb Abboud, Chairman and CEO of GHIC. “By leveraging the commitment and contributions of our investors and partners, the Global Health Security Fund is accelerating transformational technologies to achieve our shared vision for a safer and healthier world.”
Through this investment and strategic collaboration with GHIC, Meiji Seika Pharma—one of the leading pharmaceutical companies in the field of infectious diseases—aims to further advance innovation and R&D activities in this field and to contribute to addressing critical global health challenges, including future pandemics and AMR.
About Global Health Investment Corporation
Global Health Investment Corporation (GHIC) is a mission-driven nonprofit organization that has been investing in global health innovation for over a decade. Through investments in life sciences and healthcare technology companies, GHIC accelerates the development and accessibility of products with the potential to improve global public health and health equity, while also generating sustainable financial returns.
For more information, please visit https://ghicfunds.org/.
About Meiji Seika Pharma
Since launching penicillin in 1946, Meiji Seika Pharma has been committed to delivering high-quality pharmaceutical products, including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system and hematologic disorders, as well as generic medicines. Through continued investment in next-generation innovations and strategic global partnerships, Meiji Seika Pharma remains dedicated to advancing global health.
For more information, please visit https://www.meiji.com/global/pharmaceuticals/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260529122705/en/
Contacts
For further information, please contact:
Sho Takahata
Boston Office (‘START Office’), Meiji Pharma USA Inc.
E-mail: mpu.start@meiji.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
Meilleurtaux Accelerates AI Strategy as First Broker to Launch Mortgage Lending App on ChatGPT in France29.5.2026 10:00:00 EEST | Press release
Meilleurtaux, a leading omnichannel financial services brokerage platform (credit, insurance, investments), announced today the launch of a dedicated mortgage lending app directly within ChatGPT, OpenAI’s artificial intelligence platform, which now has several hundred million active users worldwide. With this new service, Meilleurtaux reaches another milestone in its “AI First” strategy and reinforces its commitment to supporting French consumers in the adoption of artificial intelligence. Simulating a Mortgage in ChatGPT: Simple, Fast, No Forms Required Until now, obtaining a borrowing capacity simulation meant browsing a website, filling out forms, and waiting for a response. Meilleurtaux has changed that: users can now run simulations directly within ChatGPT, using natural language, just like in a conversation. In only a few exchanges, users receive: a personalized borrowing capacity simulation using Meilleurtaux’s real-time rates; an assessment of the feasibility of their property
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom